

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method for [[the]] treating multiple myeloma comprising administering to an individual a therapeutically effective amount of a composition comprising an anti-alpha4 integrin antibody ~~homolog~~ or antigen binding fragment thereof.

2. (Currently amended) The method of claim 1, wherein the antibody ~~homolog~~ or antigen binding fragment thereof is an anti-alpha4/beta1 (VLA4) (VLA-4) antibody ~~homolog~~ or antigen binding fragment thereof.

3 (Canceled)

4. (Currently amended) The method of claim 1, wherein the anti-alpha4 integrin antibody ~~homolog~~ or antigen binding fragment thereof is selected from the group consisting of a) an antibody ~~homolog~~ or antigen binding fragment thereof that antagonizes the interaction of both VLA-4 and alpha4beta 7 with their respective alpha4 ligands; b) an antibody ~~homolog~~ or antigen binding fragment thereof that antagonizes the interaction of VLA-4 with its alpha4 ligand; and c) an antibody ~~homolog~~ or antigen binding fragment thereof that antagonizes the interaction of alpha4beta7 with its alpha4 ligand.

5. (Currently amended) The method of claim 4, wherein the antibody ~~homolog~~ or antigen binding fragment thereof is selected from the group consisting of a human antibody, a chimeric

antibody, [[and]] a humanized antibody and an antigen-binding Fab, Fab', F(ab')₂ or F(v) fragment of a human, chimeric or humanized antibody.

6-8 (Canceled)

9. (Currently amended) The method of claim 1, wherein the composition is administered at a dosage so as to provide from about 0.1 to about 20 mg/kg body weight of the antibody ~~homolog~~ or antigen binding fragment thereof.

10-30 (Canceled)

31. (Currently amended) The method of claim 1, wherein the antibody ~~homolog~~ or antigen binding fragment thereof is a human antibody or antigen binding fragment thereof or a humanized antibody or antigen binding fragment thereof.

32. (Currently amended) The method of claim 2, wherein the antibody ~~homolog~~ or antigen binding fragment thereof is a human antibody or antigen binding fragment thereof or a humanized antibody or antigen binding fragment thereof.

33-39. (Canceled)

40. (Currently amended) The method of claim 2, wherein the anti-VLA-4 antibody ~~homolog or antigen binding fragment thereof~~ is a humanized anti-VLA-4 antibody or antigen binding fragment thereof ~~comprising a humanized light chain and a humanized heavy chain, the light chain and the heavy chain each comprising complementarity determining regions (CDR1, CDR2 and CDR3) from murine 21.6 anti-VLA-4 antibody.~~

41. (Canceled)

42. (New) The method of claims 1 or 2, wherein the antibody or antigen-binding fragment thereof is a monoclonal antibody, or antigen-binding fragment thereof.

43. (New) The method of any one of claims 2, 32 or 40, wherein the anti-VLA-4 antibody or antigen-binding fragment thereof binds the alpha chain of VLA-4.

44. (New) The method of any one of claims 2, 32 or 40, wherein the anti-VLA-4 antibody or antigen-binding fragment thereof is a B epitope specific anti-VLA-4 antibody or antigen-binding fragment thereof.